Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 receptor antagonist ELN441958

被引:23
|
作者
Hawkinson, Jon E.
Szoke, Balazs G.
Garofalo, Albert W.
Hom, Dennis S.
Zhang, Hongbing
Dreyer, Mark
Fukuda, Juri Y.
Chen, Linda
Samant, Bhushan
Simmonds, Stellanie
Zeitz, Karla P.
Wadsworth, Angie
Liao, Anna
Chavez, Raymond A.
Zmolek, Wes
Ruslim, Lany
Bova, Michael P.
Holcomb, Ryan
Butelman, Eduardo R.
Ko, Mei-Chuan
Malmberg, Annika B.
机构
[1] Elan Pharmaceut, Lead Discovery & Optimizat, San Francisco, CA 94080 USA
[2] Rockefeller Univ, Lab Biol Addict Dis, New York, NY 10021 USA
[3] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA
关键词
D O I
10.1124/jpet.107.120352
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The bradykinin B-1 receptor plays a critical role in chronic pain and inflammation, although efforts to demonstrate efficacy of receptor antagonists have been hampered by species-dependent potency differences, metabolic instability, and low oral exposure of current agents. The pharmacology, pharmacokinetics, and analgesic efficacy of the novel benzamide B-1 receptor antagonist 7-chloro-2-[3-(9-pyridin-4-yl-3,9-diazaspiro[ 5.5]undecanecarbonyl)phenyl]-2,3-dihydro-isoindol-1-one (ELN441958) is described. ELN441958 competitively inhibited the binding of the B-1 agonist ligand [3H]desArg(10-)kallidin ([3H]DAKD) to IMR-90 human fibroblast membranes with high affinity (K-i = 0.26 +/- 0.02 nM). ELN441958 potently antagonized DAKD ( but not bradykinin)-induced calcium mobilization in IMR-90 cells, indicating that it is highly selective for B-1 over B-2 receptors. Antagonism of agonist-induced calcium responses at B-1 receptors from different species indicated that ELN441958 is selective for primate over rodent B-1 receptors with a rank order potency (K-B, nanomolar) of human (0.12 +/- 0.02) similar to rhesus monkey (0.24 +/- 0.01) similar to rat (1.5 +/- 0.4) > mouse (14 +/- 4). ELN441958 had good permeability and metabolic stability in vitro consistent with high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. Because ELN441958 is up to 120-fold more potent at primate than at rodent B1 receptors, it was evaluated in a primate pain model. ELN441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED50 similar to 3 mg/kg s.c. Naltrexone had no effect on the antihyperalgesia produced by ELN441958, indicating a lack of involvement of opioid receptors. ELN441958 is a novel small molecule bradykinin B-1 receptor antagonist exhibiting high oral bioavailability and potent systemic efficacy in rhesus monkey inflammatory pain.
引用
收藏
页码:619 / 630
页数:12
相关论文
共 50 条
  • [1] Novel pharmacological selectivity of the cloned murine B1 bradykinin receptor
    Yanagawa, T
    Prado, GN
    Cousins, B
    Navarro, J
    MOLECULAR BIOLOGY OF THE CELL, 1996, 7 : 2529 - 2529
  • [2] In vitro pharmacological characterization of the nonpeptide bradykinin B1 receptor antagonist SSR240612
    Spagnol, M.
    Camarda, V.
    Vergura, R.
    Rizzi, A.
    Calo, G.
    Gougat, J.
    Ferrari, B.
    Regoli, D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 83 - 83
  • [3] Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor
    Fox, A
    Kaur, S
    Li, BF
    Panesar, M
    Saha, U
    Davis, C
    Dragoni, I
    Colley, S
    Ritchie, T
    Bevan, S
    McIntyre, P
    BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (07) : 889 - 899
  • [4] A NOVEL GENERATION OF PEPTIDIC BRADYKININ B1 RECEPTOR ANTAGONIST BEARING LIPIDIC MOIETY
    Guerin, B.
    Neugebauer, W. A.
    Gobeil, F., Jr.
    Regoli, D.
    Sirois, P.
    Battistini, B.
    JOURNAL OF PEPTIDE SCIENCE, 2004, 10 : 246 - 246
  • [5] A novel generation of peptidic bradykinin B1 receptor antagonist bearing lipidic moiety
    Guerin, Brigitte
    Neugebauer, Witold A.
    Gobeil, Fernand, Jr.
    Regoli, Domenico
    Sirois, Pierre
    Battistini, Bruno
    Peptides 2004, Proceedings: BRIDGES BETWEEN DISCIPLINES, 2005, : 856 - 857
  • [6] Analgesic activity of bradykinin B1 receptor antagonists in rats and rabbits
    Hornok, K.
    Farkas, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 87 - 87
  • [7] Evidence of a bradykinin B1 receptor in human ileum: Pharmacological comparison to the rabbit aorta B1 receptor
    Zuzack, JS
    Burkard, MR
    Cuadrado, DK
    Greer, RA
    Selig, WM
    Whalley, ET
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 277 (03): : 1337 - 1343
  • [8] Pharmacological evaluation of a selective bradykinin B1 antagonist in a canine model of arthritis
    Duclos, B. A.
    Rugg, C. A.
    White, J.
    Ross, J. T.
    Darling, M.
    Huczek, D.
    Curry, J.
    Alexander-Bowman, S.
    Townley, A.
    Garcia-Tapia, D.
    Chio, C.
    Kamerling, S.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2017, 40 (01) : 70 - 76
  • [9] Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist
    Ransom, RW
    Harrell, CM
    Reiss, DR
    Murphy, KL
    Chang, RSL
    Hess, JF
    Miller, PJ
    O'Malley, SS
    Hey, PJ
    Kunapuli, P
    Su, DS
    Markowitz, MK
    Wallace, MA
    Raab, CE
    Jones, AN
    Dean, DC
    Pettibone, DJ
    Freidinger, RM
    Bock, MG
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 499 (1-2) : 77 - 84
  • [10] Neuroprotection by a bradykinin B2 receptor antagonist after traumatic brain injury is not attenuated by the simultaneous application of a bradykinin B1 receptor antagonist
    Görlach, C
    Hortobágyi, T
    Hortobágyi, S
    Benyó, Z
    Relton, JK
    Whalley, ET
    Wahl, M
    JOURNAL OF PHYSIOLOGY-LONDON, 2000, 526 : 50P - 51P